Rapid Eye Movement Sleep Behavior Disorder Clinical Trial
Official title:
A Randomized, Double-blind, Multi-center Clinical Study of the Efficacy of Idebenone in the Treatment of Primary Rapid Eye Movement Sleep Behavior Disorder Into Synucleinopathies
142 cases of patients with iRBD will be recruited from the neurology department of Ruijin Hospital, th second Affiliated Hospital of Soochow University and wuhan Union Hospital. After the informed consent was signed, they were divided into a trial group and a control group randomly. Each group contains 71 cases. The patients in the trial group will be treated with Idebenone, while the patients in the control group was treated with placebo. Both groups of subjects will be treated for 5 years, and patients will be followed-up and evaluated in the first year, 3 years and 5 years after treatment. The observations include the MDS-UPDRS questionnaires evaluation, blood biomarker measurements and fMRI or PET-MR examination to make sure whether the patients has converted to synucleinopathies. Study hypothesis: Idebenone therapy for patients with iRBD is safe and effective in delaying disease progression into synucleinopathies.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05307770 -
Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder
|
N/A | |
| Active, not recruiting |
NCT00817726 -
RBD Longitudinal as Prognostic for PD
|
||
| Active, not recruiting |
NCT04020198 -
A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies
|
||
| Recruiting |
NCT04886076 -
Sleep Profiles in REM Sleep Behavior Disorder
|